Characteristics | Lapatinib + paclitaxel (n = 222) | Placebo + paclitaxel (n = 222) |
---|---|---|
Median age, years (range) | 50.0 (25-74) | 50.5 (26-73) |
Race, n (%) | Â | Â |
  Asian | 192 (86) | 192 (86) |
  Other | 30 (14) | 30 (14) |
ECOG performance status, n (%) | Â | Â |
  0 | 103 (46) | 113 (51) |
  1 | 119 (54) | 109 (49) |
Central HER2 FISH + a, n (%) | 219 (99) | 218 (99) |
Hormone receptor-positive, n (%) | 111 (50) | 113 (51) |
Any visceral disease, n (%) | 187 (84) | 186 (84) |
Median time since first diagnosis, months | 25.7 | 23.6 |
Prior anticancer therapies b , n (%) | Â | Â |
  Any therapy | 171 (77) | 182 (82) |
  Chemotherapy | 160 (72) | 173 (78) |
  Adjuvant | 146 (66) | 161 (73) |
  Hormonal therapy | 53 (24) | 44 (20) |
  Biologic | 0 | 4 (2) |
  Radiotherapy | 94 (42) | 85 (38) |